BULLFROG AI HOLDINGS, INC. Revenue from Contract with Customer, Excluding Assessed Tax
BULLFROG AI HOLDINGS, INC. (BFRG) reported Revenue from Contract with Customer, Excluding Assessed Tax of $215.38 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Income Statement › Revenue
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax · last filed 2026-08-14
- BULLFROG AI HOLDINGS, INC. revenue from contract with customer, excluding assessed tax for the quarter ending 2026-06-30 was $215.38K, a 547.64% increase year-over-year.
- BULLFROG AI HOLDINGS, INC. revenue from contract with customer, excluding assessed tax for the quarter ending 2025-12-31 was $0.00.
- BULLFROG AI HOLDINGS, INC. revenue from contract with customer, excluding assessed tax for the quarter ending 2025-09-30 was $83.41K.
- BULLFROG AI HOLDINGS, INC. revenue from contract with customer, excluding assessed tax for the quarter ending 2025-06-30 was $33.26K.
- BULLFROG AI HOLDINGS, INC. revenue from contract with customer, excluding assessed tax for fiscal 2025 was $116.67K.
- BULLFROG AI HOLDINGS, INC. revenue from contract with customer, excluding assessed tax for fiscal 2023 was $65.00K, a 550.00% increase from fiscal 2022.
- BULLFROG AI HOLDINGS, INC. revenue from contract with customer, excluding assessed tax for fiscal 2022 was $10.00K.
| Period end | Revenue from Contract with Customer, Excluding Assessed Tax 3 month | Revenue from Contract with Customer, Excluding Assessed Tax 6 month | Revenue from Contract with Customer, Excluding Assessed Tax 9 month | Revenue from Contract with Customer, Excluding Assessed Tax 12 month |
|---|---|---|---|---|
| 2026-06-30 | $215.38K 10-Q · filed 2026-08-14 | $215.38K 10-Q · filed 2026-08-14 | ||
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | $83.41K derived: sum of 2 quarters · filed 2026-03-19 | $116.67K derived: sum of 3 quarters · filed 2026-08-14 | $116.67K 10-K · filed 2026-03-19 |
| 2025-09-30 | $83.41K 10-Q · filed 2025-11-14 | $116.67K derived: sum of 2 quarters · filed 2026-08-14 | $116.67K 10-Q · filed 2025-11-14 | |
| 2025-06-30 | $33.26K 10-Q · filed 2026-08-14 | $33.26K 10-Q · filed 2026-08-14 | ||
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-14 | $65.00K derived: sum of 2 quarters · filed 2025-03-14 | $65.00K 10-K · filed 2025-03-14 | |
| 2023-09-30 | $65.00K 10-Q · filed 2024-11-08 | $65.00K 10-Q · filed 2024-11-08 | ||
| 2022-12-31 | $10.00K 10-K · filed 2024-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Vyome Holdings, Inc (HIND) | United States | $0.014B | -1.38 |
| Tvardi Therapeutics, Inc. (TVRD) | United States | $0.014B | |
| LISATA THERAPEUTICS, INC. (LSTA) | United States | $0.014B | -2.13 |
| ACTUATE THERAPEUTICS, INC. (ACTU) | United States | $0.015B | |
| Vistagen Therapeutics, Inc. (VTGN) | United States | $0.013B | -0.14 |
| MUSTANG BIO, INC. (MBIO) | United States | $0.013B | |
| Anebulo Pharmaceuticals, Inc. (ANEB) | United States | $0.015B | |
| AEON Biopharma, Inc. (AEON) | United States | $0.013B | -0.36 |
| Lantern Pharma Inc. (LTRN) | United States | $0.015B | -2.87 |
| Tempest Therapeutics, Inc. (TPST) | United States | $0.013B |